HighTower Advisors
CAPR icon

HighTower Advisors’s Capricor Therapeutics CAPR Stock Holding History

HighTower Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48,800
Closed -$116K – 3703
2025
Q3 		$116K Buy
+48,800
New +$359K ﹤0.01% 3516
2024
Q2 		– Sell
-5,000
Closed -$500 – 3717
2024
Q1 		$500 Buy
+5,000
New +$24.2K ﹤0.01% 3545

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighTower Advisors's CAPR Position: Q4 2025 in Review

HighTower Advisors sold out of Capricor Therapeutics (CAPR) in Q4 2025, closing a stake of 1,200 shares — an estimated $8.65K sold.

HighTower Advisors first reported a position in CAPR in Q2 2020 and held it in 17 quarters. The position peaked at $215K in Q3 2021. 132 funds tracked by Wall St. Rank hold CAPR as of Q4 2025.

  • HighTower Advisors reported no remaining Capricor Therapeutics position as of Q4 2025 after selling out during the quarter.
  • HighTower Advisors sold 1,200 Capricor Therapeutics shares in Q4 2025, an estimated $8.65K.
  • HighTower Advisors first reported a position in Capricor Therapeutics in Q2 2020 and held it in 17 quarters.
  • HighTower Advisors's Capricor Therapeutics position peaked at $215K in Q3 2021.
  • 132 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2025.

Based on HighTower Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.